Table of Content

1 Report Overview
1.1 Tumor Necrosis Factor Inhibitors Drug Definition
1.2 Market by Type
1.2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Cimzia (Certolizumab Pegol)
1.2.3 Enbrel (Etanercept)
1.2.4 Humira ( Adalimumab)
1.2.5 Otezla (Apremilast)
1.2.6 Remicade (Infliximab)
1.2.7 Simponi (Golimumab)
1.3 Market Segment by Application
1.3.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Tumor Necrosis Factor Inhibitors Drug Sales
2.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region
2.3.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2018-2023)
2.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2024-2034)
2.4 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Region
2.6.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Manufacturers
3.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Drug Sales in 2024
3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers
3.2.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Drug Revenue in 2024
3.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Price by Manufacturers
3.4 Global Key Players of Tumor Necrosis Factor Inhibitors Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Tumor Necrosis Factor Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Product Offered and Application
3.8 Global Key Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type
4.1.1 Global Tumor Necrosis Factor Inhibitors Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type
4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2018-2034)
4.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Type
4.3.1 Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2018-2023)
4.3.2 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application
5.1.1 Global Tumor Necrosis Factor Inhibitors Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application
5.2.1 Global Tumor Necrosis Factor Inhibitors Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2018-2034)
5.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Application
5.3.1 Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2018-2023)
5.3.2 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Company
6.1.1 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023)
6.1.2 North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023)
6.2 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Type
6.2.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2034)
6.3 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Application
6.3.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2034)
6.4 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Country
6.4.1 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2018-2034)
6.4.3 North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Company
7.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023)
7.2 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Type
7.2.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2034)
7.3 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Application
7.3.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2034)
7.4 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Country
7.4.1 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2018-2034)
7.4.3 Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Tumor Necrosis Factor Inhibitors Drug Sales by Company
8.1.1 China Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023)
8.1.2 China Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023)
8.2 China Tumor Necrosis Factor Inhibitors Drug Market Size by Type
8.2.1 China Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2034)
8.2.2 China Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2034)
8.3 China Tumor Necrosis Factor Inhibitors Drug Market Size by Application
8.3.1 China Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2034)
8.3.2 China Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Company
9.1.1 APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023)
9.2 APAC Tumor Necrosis Factor Inhibitors Drug Market Size by Type
9.2.1 APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2034)
9.3 APAC Tumor Necrosis Factor Inhibitors Drug Market Size by Application
9.3.1 APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2034)
9.4 APAC Tumor Necrosis Factor Inhibitors Drug Market Size by Region
9.4.1 APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2018-2034)
9.4.3 APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Apogenix
11.1.1 Apogenix Company Information
11.1.2 Apogenix Overview
11.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Products and Services
11.1.5 Apogenix Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.1.6 Apogenix Recent Developments
11.2 AryoGen Biopharma
11.2.1 AryoGen Biopharma Company Information
11.2.2 AryoGen Biopharma Overview
11.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Products and Services
11.2.5 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.2.6 AryoGen Biopharma Recent Developments
11.3 Bionovis
11.3.1 Bionovis Company Information
11.3.2 Bionovis Overview
11.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Products and Services
11.3.5 Bionovis Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.3.6 Bionovis Recent Developments
11.4 CASI Pharmaceuticals
11.4.1 CASI Pharmaceuticals Company Information
11.4.2 CASI Pharmaceuticals Overview
11.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products and Services
11.4.5 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.4.6 CASI Pharmaceuticals Recent Developments
11.5 Celltrion
11.5.1 Celltrion Company Information
11.5.2 Celltrion Overview
11.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Products and Services
11.5.5 Celltrion Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.5.6 Celltrion Recent Developments
11.6 Celgene Corporation
11.6.1 Celgene Corporation Company Information
11.6.2 Celgene Corporation Overview
11.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Products and Services
11.6.5 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.6.6 Celgene Corporation Recent Developments
11.7 Delenex Therapeutics
11.7.1 Delenex Therapeutics Company Information
11.7.2 Delenex Therapeutics Overview
11.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Products and Services
11.7.5 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.7.6 Delenex Therapeutics Recent Developments
11.8 Dexa Medica
11.8.1 Dexa Medica Company Information
11.8.2 Dexa Medica Overview
11.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Products and Services
11.8.5 Dexa Medica Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.8.6 Dexa Medica Recent Developments
11.9 EPIRUS Biopharmaceuticals
11.9.1 EPIRUS Biopharmaceuticals Company Information
11.9.2 EPIRUS Biopharmaceuticals Overview
11.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products and Services
11.9.5 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.9.6 EPIRUS Biopharmaceuticals Recent Developments
11.10 Janssen Biotech
11.10.1 Janssen Biotech Company Information
11.10.2 Janssen Biotech Overview
11.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Products and Services
11.10.5 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
11.10.6 Janssen Biotech Recent Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Information
11.11.2 GlaxoSmithKline Overview
11.11.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Products and Services
11.11.5 GlaxoSmithKline Recent Developments
11.12 HanAll Biopharma
11.12.1 HanAll Biopharma Company Information
11.12.2 HanAll Biopharma Overview
11.12.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Products and Services
11.12.5 HanAll Biopharma Recent Developments
11.13 Intas Pharmaceuticals
11.13.1 Intas Pharmaceuticals Company Information
11.13.2 Intas Pharmaceuticals Overview
11.13.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products and Services
11.13.5 Intas Pharmaceuticals Recent Developments
11.14 LEO Pharma
11.14.1 LEO Pharma Company Information
11.14.2 LEO Pharma Overview
11.14.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Products and Services
11.14.5 LEO Pharma Recent Developments
11.15 LG Life Sciences
11.15.1 LG Life Sciences Company Information
11.15.2 LG Life Sciences Overview
11.15.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Products and Services
11.15.5 LG Life Sciences Recent Developments
11.16 MedImmune
11.16.1 MedImmune Company Information
11.16.2 MedImmune Overview
11.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 MedImmune Tumor Necrosis Factor Inhibitors Drug Products and Services
11.16.5 MedImmune Recent Developments
11.17 Momenta Pharmaceuticals
11.17.1 Momenta Pharmaceuticals Company Information
11.17.2 Momenta Pharmaceuticals Overview
11.17.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products and Services
11.17.5 Momenta Pharmaceuticals Recent Developments
11.18 Novartis
11.18.1 Novartis Company Information
11.18.2 Novartis Overview
11.18.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 Novartis Tumor Necrosis Factor Inhibitors Drug Products and Services
11.18.5 Novartis Recent Developments
11.19 PROBIOMED
11.19.1 PROBIOMED Company Information
11.19.2 PROBIOMED Overview
11.19.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.19.4 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Products and Services
11.19.5 PROBIOMED Recent Developments
11.20 Reliance Life Sciences
11.20.1 Reliance Life Sciences Company Information
11.20.2 Reliance Life Sciences Overview
11.20.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.20.4 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Products and Services
11.20.5 Reliance Life Sciences Recent Developments
11.21 Sandoz
11.21.1 Sandoz Company Information
11.21.2 Sandoz Overview
11.21.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.21.4 Sandoz Tumor Necrosis Factor Inhibitors Drug Products and Services
11.21.5 Sandoz Recent Developments
11.22 Samsung Bioepis
11.22.1 Samsung Bioepis Company Information
11.22.2 Samsung Bioepis Overview
11.22.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.22.4 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Products and Services
11.22.5 Samsung Bioepis Recent Developments
11.23 Sanofi-Aventis
11.23.1 Sanofi-Aventis Company Information
11.23.2 Sanofi-Aventis Overview
11.23.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.23.4 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Products and Services
11.23.5 Sanofi-Aventis Recent Developments
11.24 Shanghai CP Guojian Pharmaceutical
11.24.1 Shanghai CP Guojian Pharmaceutical Company Information
11.24.2 Shanghai CP Guojian Pharmaceutical Overview
11.24.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.24.4 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Products and Services
11.24.5 Shanghai CP Guojian Pharmaceutical Recent Developments
11.25 Shanghai Pharmaceuticals
11.25.1 Shanghai Pharmaceuticals Company Information
11.25.2 Shanghai Pharmaceuticals Overview
11.25.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.25.4 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products and Services
11.25.5 Shanghai Pharmaceuticals Recent Developments
11.26 Simcere Pharmaceutical
11.26.1 Simcere Pharmaceutical Company Information
11.26.2 Simcere Pharmaceutical Overview
11.26.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.26.4 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Products and Services
11.26.5 Simcere Pharmaceutical Recent Developments
11.27 Toyama Chemical
11.27.1 Toyama Chemical Company Information
11.27.2 Toyama Chemical Overview
11.27.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.27.4 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Products and Services
11.27.5 Toyama Chemical Recent Developments
11.28 Tsumura
11.28.1 Tsumura Company Information
11.28.2 Tsumura Overview
11.28.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.28.4 Tsumura Tumor Necrosis Factor Inhibitors Drug Products and Services
11.28.5 Tsumura Recent Developments
11.29 UCB
11.29.1 UCB Company Information
11.29.2 UCB Overview
11.29.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.29.4 UCB Tumor Necrosis Factor Inhibitors Drug Products and Services
11.29.5 UCB Recent Developments
11.30 Zydus Cadila
11.30.1 Zydus Cadila Company Information
11.30.2 Zydus Cadila Overview
11.30.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.30.4 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Products and Services
11.30.5 Zydus Cadila Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Tumor Necrosis Factor Inhibitors Drug Value Chain Analysis
12.2 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Tumor Necrosis Factor Inhibitors Drug Production Mode & Process
12.4 Tumor Necrosis Factor Inhibitors Drug Sales and Marketing
12.4.1 Tumor Necrosis Factor Inhibitors Drug Sales Channels
12.4.2 Tumor Necrosis Factor Inhibitors Drug Distributors
12.5 Tumor Necrosis Factor Inhibitors Drug Customers
13 Market Dynamics
13.1 Tumor Necrosis Factor Inhibitors Drug Industry Trends
13.2 Tumor Necrosis Factor Inhibitors Drug Market Drivers
13.3 Tumor Necrosis Factor Inhibitors Drug Market Challenges
13.4 Tumor Necrosis Factor Inhibitors Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Cimzia (Certolizumab Pegol)
Table 3. Major Manufacturers of Enbrel (Etanercept)
Table 4. Major Manufacturers of Humira ( Adalimumab)
Table 5. Major Manufacturers of Otezla (Apremilast)
Table 6. Major Manufacturers of Remicade (Infliximab)
Table 7. Major Manufacturers of Simponi (Golimumab)
Table 8. Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2018-2023) & (US$ Million)
Table 11. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2018-2023)
Table 12. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2024-2034) & (US$ Million)
Table 13. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2024-2034)
Table 14. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 15. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2018-2023) & (K Pcs)
Table 16. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2018-2023)
Table 17. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2024-2034) & (K Pcs)
Table 18. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2024-2034)
Table 19. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 20. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 21. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 22. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers (2018-2023)
Table 23. Global Tumor Necrosis Factor Inhibitors Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 24. Global Key Players of Tumor Necrosis Factor Inhibitors Drug, Industry Ranking, 2021 VS 2024
Table 25. Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Tumor Necrosis Factor Inhibitors Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor Inhibitors Drug as of 2024)
Table 27. Global Key Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Product Offered and Application
Table 29. Global Key Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 32. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 33. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Share by Type (2018-2023)
Table 34. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Share by Type (2024-2034)
Table 35. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2023) & (US$ Million)
Table 36. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2024-2034) & (US$ Million)
Table 37. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2018-2023)
Table 38. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2024-2034)
Table 39. Tumor Necrosis Factor Inhibitors Drug Price by Type (2018-2023) & (USD/Pcs)
Table 40. Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 41. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 42. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 43. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Share by Application (2018-2023)
Table 44. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Share by Application (2024-2034)
Table 45. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2023) & (US$ Million)
Table 46. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2024-2034) & (US$ Million)
Table 47. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Application (2018-2023)
Table 48. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Application (2024-2034)
Table 49. Tumor Necrosis Factor Inhibitors Drug Price by Application (2018-2023) & (USD/Pcs)
Table 50. Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 51. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023) & (US$ Million)
Table 52. North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 53. North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 54. North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 55. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2023) & (US$ Million)
Table 56. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2024-2034) & (US$ Million)
Table 57. North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 58. North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 59. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2023) & (US$ Million)
Table 60. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2024-2034) & (US$ Million)
Table 61. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 62. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2018-2023) & (US$ Million)
Table 63. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2024-2034) & (US$ Million)
Table 64. North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 65. North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 66. Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 67. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023) & (US$ Million)
Table 68. Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 69. Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 70. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2023) & (US$ Million)
Table 71. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2024-2034) & (US$ Million)
Table 72. Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 73. Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 74. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2023) & (US$ Million)
Table 75. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2024-2034) & (US$ Million)
Table 76. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 77. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2018-2023) & (US$ Million)
Table 78. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2024-2034) & (US$ Million)
Table 79. Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 80. Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 81. China Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 82. China Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023) & (US$ Million)
Table 83. China Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 84. China Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 85. China Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2023) & (US$ Million)
Table 86. China Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2024-2034) & (US$ Million)
Table 87. China Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 88. China Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 89. China Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2023) & (US$ Million)
Table 90. China Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2024-2034) & (US$ Million)
Table 91. APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 92. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023) & (US$ Million)
Table 93. APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 94. APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 95. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2023) & (US$ Million)
Table 96. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2024-2034) & (US$ Million)
Table 97. APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 98. APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 99. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2023) & (US$ Million)
Table 100. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2024-2034) & (US$ Million)
Table 101. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 102. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2018-2023) & (US$ Million)
Table 103. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2024-2034) & (US$ Million)
Table 104. APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 105. APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 106. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 107. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 109. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 110. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 113. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 114. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 117. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2018-2023) & (US$ Million)
Table 118. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2024-2034) & (US$ Million)
Table 119. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 120. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 121. Apogenix Company Information
Table 122. Apogenix Description and Overview
Table 123. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 124. Apogenix Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 125. Apogenix Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 126. Apogenix Recent Developments
Table 127. AryoGen Biopharma Company Information
Table 128. AryoGen Biopharma Description and Overview
Table 129. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 130. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 131. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 132. AryoGen Biopharma Recent Developments
Table 133. Bionovis Company Information
Table 134. Bionovis Description and Overview
Table 135. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 136. Bionovis Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 137. Bionovis Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 138. Bionovis Recent Developments
Table 139. CASI Pharmaceuticals Company Information
Table 140. CASI Pharmaceuticals Description and Overview
Table 141. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 142. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 143. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 144. CASI Pharmaceuticals Recent Developments
Table 145. Celltrion Company Information
Table 146. Celltrion Description and Overview
Table 147. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 148. Celltrion Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 149. Celltrion Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 150. Celltrion Recent Developments
Table 151. Celgene Corporation Company Information
Table 152. Celgene Corporation Description and Overview
Table 153. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 154. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 155. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 156. Celgene Corporation Recent Developments
Table 157. Delenex Therapeutics Company Information
Table 158. Delenex Therapeutics Description and Overview
Table 159. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 160. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 161. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 162. Delenex Therapeutics Recent Developments
Table 163. Dexa Medica Company Information
Table 164. Dexa Medica Description and Overview
Table 165. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 166. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 167. Dexa Medica Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 168. Dexa Medica Recent Developments
Table 169. EPIRUS Biopharmaceuticals Company Information
Table 170. EPIRUS Biopharmaceuticals Description and Overview
Table 171. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 172. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 173. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 174. EPIRUS Biopharmaceuticals Recent Developments
Table 175. Janssen Biotech Company Information
Table 176. Janssen Biotech Description and Overview
Table 177. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 178. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 179. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug SWOT Analysis
Table 180. Janssen Biotech Recent Developments
Table 181. GlaxoSmithKline Company Information
Table 182. GlaxoSmithKline Description and Overview
Table 183. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 184. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 185. GlaxoSmithKline Recent Developments
Table 186. HanAll Biopharma Company Information
Table 187. HanAll Biopharma Description and Overview
Table 188. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 189. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 190. HanAll Biopharma Recent Developments
Table 191. Intas Pharmaceuticals Company Information
Table 192. Intas Pharmaceuticals Description and Overview
Table 193. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 194. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 195. Intas Pharmaceuticals Recent Developments
Table 196. LEO Pharma Company Information
Table 197. LEO Pharma Description and Overview
Table 198. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 199. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 200. LEO Pharma Recent Developments
Table 201. LG Life Sciences Company Information
Table 202. LG Life Sciences Description and Overview
Table 203. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 204. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 205. LG Life Sciences Recent Developments
Table 206. MedImmune Company Information
Table 207. MedImmune Description and Overview
Table 208. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 209. MedImmune Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 210. MedImmune Recent Developments
Table 211. Momenta Pharmaceuticals Company Information
Table 212. Momenta Pharmaceuticals Description and Overview
Table 213. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 214. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 215. Momenta Pharmaceuticals Recent Developments
Table 216. Novartis Company Information
Table 217. Novartis Description and Overview
Table 218. Novartis Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 219. Novartis Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 220. Novartis Recent Developments
Table 221. PROBIOMED Company Information
Table 222. PROBIOMED Description and Overview
Table 223. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 224. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 225. PROBIOMED Recent Developments
Table 226. Reliance Life Sciences Company Information
Table 227. Reliance Life Sciences Description and Overview
Table 228. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 229. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 230. Reliance Life Sciences Recent Developments
Table 231. Sandoz Company Information
Table 232. Sandoz Description and Overview
Table 233. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 234. Sandoz Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 235. Sandoz Recent Developments
Table 236. Samsung Bioepis Company Information
Table 237. Samsung Bioepis Description and Overview
Table 238. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 239. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 240. Samsung Bioepis Recent Developments
Table 241. Sanofi-Aventis Company Information
Table 242. Sanofi-Aventis Description and Overview
Table 243. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 244. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 245. Sanofi-Aventis Recent Developments
Table 246. Shanghai CP Guojian Pharmaceutical Company Information
Table 247. Shanghai CP Guojian Pharmaceutical Description and Overview
Table 248. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 249. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 250. Shanghai CP Guojian Pharmaceutical Recent Developments
Table 251. Shanghai Pharmaceuticals Company Information
Table 252. Shanghai Pharmaceuticals Description and Overview
Table 253. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 254. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 255. Shanghai Pharmaceuticals Recent Developments
Table 256. Simcere Pharmaceutical Company Information
Table 257. Simcere Pharmaceutical Description and Overview
Table 258. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 259. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 260. Simcere Pharmaceutical Recent Developments
Table 261. Toyama Chemical Company Information
Table 262. Toyama Chemical Description and Overview
Table 263. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 264. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 265. Toyama Chemical Recent Developments
Table 266. Tsumura Company Information
Table 267. Tsumura Description and Overview
Table 268. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 269. Tsumura Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 270. Tsumura Recent Developments
Table 271. UCB Company Information
Table 272. UCB Description and Overview
Table 273. UCB Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 274. UCB Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 275. UCB Recent Developments
Table 276. Zydus Cadila Company Information
Table 277. Zydus Cadila Description and Overview
Table 278. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 279. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 280. Zydus Cadila Recent Developments
Table 281. Key Raw Materials Lists
Table 282. Raw Materials Key Suppliers Lists
Table 283. Tumor Necrosis Factor Inhibitors Drug Distributors List
Table 284. Tumor Necrosis Factor Inhibitors Drug Customers List
Table 285. Tumor Necrosis Factor Inhibitors Drug Market Trends
Table 286. Tumor Necrosis Factor Inhibitors Drug Market Drivers
Table 287. Tumor Necrosis Factor Inhibitors Drug Market Challenges
Table 288. Tumor Necrosis Factor Inhibitors Drug Market Restraints
Table 289. Research Programs/Design for This Report
Table 290. Key Data Information from Secondary Sources
Table 291. Key Data Information from Primary Sources
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitors Drug Product Picture
Figure 2. Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Tumor Necrosis Factor Inhibitors Drug Market Share by Type in 2024 & 2034
Figure 4. Cimzia (Certolizumab Pegol) Product Picture
Figure 5. Enbrel (Etanercept) Product Picture
Figure 6. Humira ( Adalimumab) Product Picture
Figure 7. Otezla (Apremilast) Product Picture
Figure 8. Remicade (Infliximab) Product Picture
Figure 9. Simponi (Golimumab) Product Picture
Figure 10. Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 11. Global Tumor Necrosis Factor Inhibitors Drug Market Share by Application in 2024 & 2034
Figure 12. Clinic
Figure 13. Hospital
Figure 14. Others
Figure 15. Tumor Necrosis Factor Inhibitors Drug Report Years Considered
Figure 16. Global Tumor Necrosis Factor Inhibitors Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 17. Global Tumor Necrosis Factor Inhibitors Drug Revenue 2018-2034 (US$ Million)
Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 19. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity 2018-2034 (K Pcs)
Figure 20. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Market Share by Region (2018-2023)
Figure 21. Global Tumor Necrosis Factor Inhibitors Drug Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Tumor Necrosis Factor Inhibitors Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. North America Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Tumor Necrosis Factor Inhibitors Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. Europe Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Tumor Necrosis Factor Inhibitors Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. China Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Tumor Necrosis Factor Inhibitors Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. APAC Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 31. Middle East, Africa and Latin America Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Tumor Necrosis Factor Inhibitors Drug Sales Quantity in 2024
Figure 33. The Top 10 and Top 5 Players Market Share by Tumor Necrosis Facto